Date | Zevra Therapeutics - Part 3

X

NOW AVAILABLE IN THE U.S.

Visit MIPLYFFA.com

Arimoclomol in adults with NPC in a real-world setting: Long-term data from an expanded access program in the USA

April 15, 2024/in 2025-2024, Medical Presentations/by Jeff Lorber

Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002

October 4, 2023/in 2023-2022, Medical Presentations/by David Anderson

Real World Data Collection in Niemann-Pick Disease Type C – Data from Expanded Access Program with Arimoclomol

October 4, 2023/in 2023-2022, Medical Presentations/by David Anderson

Cardiovascular (CV) Safety and Pharmacokinetics (PK) of Serdexmethylphenidate (SDX), a Prodrug of d-Methylphenidate (d-MPH) Compared to Ritalin and Ritalin LA in a Single-Dose Crossover Study in Healthy Volunteers

September 8, 2023/in 2023-2022, Presentations/by eallison

Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

July 3, 2023/in 2023-2022, Publications/by David Anderson

A Clinical Study with KP1077 in Adults with Idiopathic Hypersomnia

June 7, 2023/in 2023-2022, Presentations/by David Anderson

Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale

April 4, 2023/in 2021-2020, Medical Publications/by David Anderson

Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

April 4, 2023/in 2021-2020, Medical Publications/by David Anderson

Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment

March 1, 2023/in 2021-2020, Medical Publications/by David Anderson

Association Between NPC Severity Score Domains and Corresponding Items of the Performance-based Scale for the Assessment and Rating of Ataxia (SARA)

February 23, 2023/in 2023-2022, Medical Presentations/by eallison